
ADC potential “standard of care” for some breast cancer patients
The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting. The drug is expected to become a standard of care for these patients,… Read More















